ported to higher brain regions. Surprisingly, they found that WGA reproducibly labeled regions with motor and affective functions-specifically neurons in a discrete but poorly studied region of the globus pallidus, and limbic regions including the amygdala, ventromedial nucleus of the hypothalamus (VMH), and bed nucleus of the stria terminalis (BNST) (Figure 1) . No other painrelated brain regions were innervated, including the parabrachial nucleus and the thalamus-two major targets of ascending nociceptive input from lamina I. The absence of labeling in thalamus suggested that nonpeptidergic circuits were not important for sensorydiscriminative aspects of pain (ex. where is the pain stimulus located, is the stimulus mechanical or thermal). Instead, nonpeptidergic neurons may be more important for conveying the motivational/affective dimensions of pain (ex. how unpleasant is the pain) to the brain. It is also important to point out that, prior to this study, the prevailing view was that lamina II did not provide substantial supraspinal projections (Gauriau and Bernard, 2002). Clearly this is not the case. Finally, at a technical level, it was impressive that the transgenic approach used by Braz and colleagues was so effective in labeling pain circuitry, up to fourth-order neurons! The connections that Braz and colleagues observed to affective regions of the brain are intriguing, particularly when considering that peptidergic-lamina I pain pathways also project to amygdala, VMH, and BNST via the parabrachial nucleus (Figure 1 ) (Gauriau and Bernard, 2002). This hints that there may be parallel pain inputs to brain regions that process affect and emotion. Admittedly, we still do not know whether these two pain pathways converge onto the same subregions (such as the central nucleus of amygdala), let alone whether they converge onto the same neurons. However, if these two pain pathways interact in the brain, they could represent interlocking circuits with feedbacks to the spinal cord. In turn, the function of these circuits might be to maintain homeostasis by motivating behaviors that reduce an organism's exposure to painful stimuli (Craig, 2003) . Interestingly, in a recent paper from Caterina's lab, it was found that P2X 3 knockout mice displayed enhanced thermal avoidance in a temperature gradient (Shimizu et al., 2005) . Since P2X 3 is expressed only in nonpeptidergic neurons, and ATP excites these neurons by opening the P2X 3 ion channel, elimination of P2X 3 could change the balance of activity within limbic regions of the brain. Altered output from these limbic regions could "motivate" P2X 3 mutant mice to more quickly seek out an optimal thermal environment. Alternatively, ATP-sensing by nonpeptidergic neurons could regulate thermal avoidance by a mechanism related to motor function, such as by modulating neurons in the globus pallidus. In keeping with this theme, pain-related activation of VMH could gate contextually appropriate appetitive, reproductive, or defensive behaviors (Choi et al., 2005; Gauriau and Bernard, 2002). In affective terms, VMH activation could motivate attraction to pleasurable stimuli or aversion to painful sensory stimuli. Ultimately, additional genetic and circuit-based experiments will be needed to determine precisely how these peptidergic and nonpeptidergic pain circuits impact somatosensory and affective behaviors. 
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Here, three groups of animals were trained in the CPP paradigm. Two days later, all groups received intraaccumbens core U1026 infusions. The first group was infused and returned to their homecages (no retrieval session) in order to control for the effects of the drug alone. The second and third groups received infusions either pre-or post-retrieval testing, respectively. One day later, all animals were tested for expression of CPP.
One would predict that the rats that did not receive the first retrieval test would display normal CPP on the second test day because reconsolidation is retrieval dependent. Indeed, this was the case. The group that received a post-test infusion of U1026 did not show CPP on the second test session (an effect that was evident even 2 weeks later), demonstrating a failure to reconsolidate memory for the drug-paired cues. Failure to reconsolidate was also associated with lower levels of phosphorylated ERK, Elk-1, CREB, and Fos in the core. Finally, rats that received pretest infusions of U1026 displayed impaired "retrieval" of the CPP memory on the first test session, replicating their first experiment. Surprisingly, these rats also failed to show a preference on the second test day. This is an unexpected result because rats with impaired retrieval should behave similarly to rats that did not receive a retrieval session at all. Although the authors do not comment on this intriguing result, the data imply that the rats in the second group probably retrieved memory for the task but were just unable to appropriately express what they retrieved regardless of the mechanism. These data reemphasize the fact that we cannot know what an animal has retrieved according to its ability to perform or express the output of that memory. Thus, the ERK pathway in the accumbens core may only be needed for the motoric expression of retrieved memories of this type. Nevertheless, the more novel and important finding is that the ability of what seems to be a drug-associated contextual memory to guide behavior can be disrupted by interfering with the reconsolidation in the accumbens core.
In the second paper, Lee et al. examined whether memory for drug-associated cues is reconsolidated within the basolateral amygdala (BLA) and, in particular, focused on the involvement of the learning-related immediately early gene/transcription factor Zif268. When a drug state has been repeatedly paired with cues in the environment, these cues become imbued with specific properties-as in the case above, they elicit Pavlovian approach and preference for the drug-paired environment. Such cues can also act as conditioned reinforcers, such that they actually support new instrumental learning. In this case, the animal learns a new response (i.e., lever pressing), reinforced solely by presentation of the previously learned cue. In other words, the cue now has reward value and can guide or influence new behavior. It is believed that such cues exert powerful control over the addict's behavior, maintaining drug seeking even in the absence of immediate reinforcement by the drug.
Zif268 is upregulated in the BLA following re-exposure to stimuli previously paired with cocaine selfadministration (Thomas et al., 2003) . Here, Lee and colleagues extend these finding by examining whether Zif268 is involved in the reconsolidation of drug-related memories. Rats were trained to self-administer cocaine by nosepoking. Cocaine infusions were paired with the illumination of a light. Following this training, the rats were given one "reactivation" session in which nosepoking results only in the presentation of the light. Prior to this session, rats were given an intra-amygdala injection of Zif268 antisense oligodeoxynucleotides or a missense control infusion. The same rats were tested several days later under new conditions (but in the same chamber) in which novel levers were extended into the chamber. Responding on the positive lever, a response control animals readily learn, resulted in presentation of the drug-paired cue. The authors find that the Zif268 antisense treatment prevented animals from later acquiring responding with conditioned reinforcement. A similar disruption in reconsolidation was found with intra-BLA antisense treatment in a fear conditioning paradigm. Thus, in the present study the authors advance knowledge of the molecular and anatomical substrates underlying reconsolidation of drug-associated memories.
Although the implications of these experiments are potentially quite profound, it is important to identify the precise behavioral deficits observed after reconsolidation is disrupted. For example, one can ask in the study presented by Lee et al. whether the CS (i.e., the light cue) retains any sort of reward value to the animal following disruption or whether its conditioned appetitive properties are simply "erased"-which would be truly extraordinary considering the resistance of drug-CS associations to extinction. Additionally, future experiments should, in addition to investigating the molecular mechanisms of reconsolidation within isolated brain regions, explore the effects of altered plasticity in one node of a network on plasticity within the entire network involved in a particular behavior. Much data suggest that stimulus-drug associations formed in the amygdala or hippocampus are integrated with a variety of nucleus accumbens-based motor outputs (e.g., Pavlovian approach or exploratory drug-seeking behaviors). Therefore, does disruption of reconsolidation within the amygdala also affect plasticity within the amygdalaaccumbens pathway that mediates motor expression of learned associations (and vice versa)? Indeed, the profile of data presented by Miller and Marshall suggests that activation of the ERK pathway in the accumbens core could be a critical molecular link between retrieved associations and the responses they invoke. Questions still remain as to whether interference with reconsolidation actually diminishes the strength of the cocaine-associated cues or the power of that association on their ability to facilitate the learning of a new motor response (i.e., Pavlovian to instrumental transfer). Nevertheless, this set of findings suggests exciting new avenues for the treatment of addiction. While cue-elicited relapse to drug use remains a daunting problem, the unforeseen lability of recalled memories offers an unexpected opportunity for the development of novel interventions.
